drugset / Trial / NCT06754644
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | QL2107 | Unknown | 200 mg | — |
| Background | Carboplatin | Small molecule | 5 mg/ml | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |